Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Neoplasms 25Rectal Neoplasms 23Glioblastoma 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Breast Neoplasms 17Pancreatic Neoplasms 16Lung Neoplasms 16Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 14Neoplasms 12Oropharyngeal Neoplasms 11Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Adenocarcinoma Of Esophagus 8Uterine Cervical Neoplasms 7Glioma 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Gliosarcoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Melanoma 5Laryngeal Neoplasms 5Colorectal Neoplasms 5Xerostomia 4Sarcoma 4Mouth Neoplasms 4

Interventions

pembrolizumab 3apatinib 3Magnetic Resonance Spectroscopy 3lenvatinib 2Specimen Handling 2Nivolumab 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1Tretinoin 1Sunitinib 1Radiation 1Pemetrexed 1Nelfinavir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lutetium-177 1Lutetium 1Ipilimumab 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Adenoid Cystic × Radiation × Clear all
NCT03087019 2022-10-14

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
21 enrolled 11 charts

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡